Acarix AB (publ) (ACARIX.ST)
SEK 0.25
(-4.05%)
SEK 0.25
(-4.05%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 6.24 Million SEK | 7.2% |
| 2022 | 5.82 Million SEK | 54.84% |
| 2021 | 3.76 Million SEK | 73.27% |
| 2020 | 2.17 Million SEK | 16.86% |
| 2019 | 1.85 Million SEK | 81.35% |
| 2018 | 1.02 Million SEK | 60.5% |
| 2017 | 638 Thousand SEK | 0.0% |
| 2016 | - SEK | 0.0% |
| 2015 | - SEK | 0.0% |
| 2014 | - SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 1.55 Million SEK | 32.2% |
| 2024 Q2 | 1.95 Million SEK | 26.16% |
| 2023 Q4 | 1.17 Million SEK | -25.37% |
| 2023 FY | 6.24 Million SEK | 7.2% |
| 2023 Q2 | 1.54 Million SEK | -21.19% |
| 2023 Q3 | 1.57 Million SEK | 2.14% |
| 2023 Q1 | 1.95 Million SEK | 18.21% |
| 2022 Q2 | 1.68 Million SEK | 26.79% |
| 2022 FY | 5.82 Million SEK | 54.84% |
| 2022 Q1 | 1.32 Million SEK | 42.78% |
| 2022 Q4 | 1.65 Million SEK | 42.01% |
| 2022 Q3 | 1.16 Million SEK | -30.71% |
| 2021 FY | 3.76 Million SEK | 73.27% |
| 2021 Q2 | 878 Thousand SEK | 21.44% |
| 2021 Q3 | 1.23 Million SEK | 40.21% |
| 2021 Q4 | 928 Thousand SEK | -24.61% |
| 2021 Q1 | 723 Thousand SEK | -25.16% |
| 2020 Q3 | 791 Thousand SEK | 170.89% |
| 2020 FY | 2.17 Million SEK | 16.86% |
| 2020 Q4 | 966 Thousand SEK | 22.12% |
| 2020 Q2 | 292 Thousand SEK | 141.32% |
| 2020 Q1 | 121 Thousand SEK | -84.37% |
| 2019 Q3 | 120 Thousand SEK | -81.93% |
| 2019 Q4 | 774 Thousand SEK | 545.0% |
| 2019 FY | 1.85 Million SEK | 81.35% |
| 2019 Q1 | 299 Thousand SEK | 43.06% |
| 2019 Q2 | 664 Thousand SEK | 122.07% |
| 2018 Q1 | 230 Thousand SEK | 0.0% |
| 2018 FY | 1.02 Million SEK | 60.5% |
| 2018 Q4 | 209 Thousand SEK | -40.46% |
| 2018 Q3 | 351 Thousand SEK | 49.36% |
| 2018 Q2 | 235 Thousand SEK | 2.17% |
| 2017 Q1 | - SEK | 0.0% |
| 2017 Q2 | 193 Thousand SEK | 0.0% |
| 2017 Q3 | 215 Thousand SEK | 11.4% |
| 2017 FY | 638 Thousand SEK | 0.0% |
| 2017 Q4 | 230 Thousand SEK | 6.98% |
| 2016 Q3 | - SEK | 0.0% |
| 2016 Q1 | - SEK | 0.0% |
| 2016 FY | - SEK | 0.0% |
| 2016 Q4 | - SEK | 0.0% |
| 2016 Q2 | - SEK | 0.0% |
| 2015 Q4 | - SEK | 0.0% |
| 2015 FY | - SEK | 0.0% |
| 2014 FY | - SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.545% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 99.545% |
| Arcoma AB | 163.01 Million SEK | 96.172% |
| Bactiguard Holding AB (publ) | 203.99 Million SEK | 96.941% |
| BICO Group AB (publ) | 2.23 Billion SEK | 99.721% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 98.908% |
| CellaVision AB (publ) | 677.29 Million SEK | 99.079% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | 24.562% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -539.263% |
| C-Rad AB (publ) | 424.61 Million SEK | 98.53% |
| Duearity AB (publ) | 1.65 Million SEK | -277.328% |
| Dignitana AB (publ) | 86.06 Million SEK | 92.748% |
| Episurf Medical AB (publ) | 10.3 Million SEK | 39.408% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.98% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | 11.829% |
| Integrum AB (publ) | 104.11 Million SEK | 94.006% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -630.199% |
| Mentice AB (publ) | 273.61 Million SEK | 97.719% |
| OssDsign AB (publ) | 112.15 Million SEK | 94.435% |
| Paxman AB (publ) | 210.11 Million SEK | 97.03% |
| Promimic AB (publ) | 37.07 Million SEK | 83.164% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -2457.787% |
| SciBase Holding AB (publ) | 23.24 Million SEK | 73.151% |
| ScandiDos AB (publ) | 60.42 Million SEK | 89.672% |
| Sectra AB (publ) | 2.96 Billion SEK | 99.789% |
| Sedana Medical AB (publ) | 153.86 Million SEK | 95.944% |
| Senzime AB (publ) | 35.75 Million SEK | 82.545% |
| SpectraCure AB (publ) | 318 Thousand SEK | -1862.579% |
| Stille AB | 294.89 Million SEK | 97.884% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 99.822% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 98.956% |